Abstract Number: 1791 • 2013 ACR/ARHP Annual Meeting
Reaching The Target Of Low Disease Activity At 6 Months Predicts Better Long-Term Functional Outcome In Patients With Early Rheumatoid Arthritis
Background/Purpose: Current clinical practice guidelines recommend remission, and if not possible, low disease activity (LDA) as the treatment target in rheumatoid arthritis (RA). Patients should…Abstract Number: 1792 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis
Background/Purpose: Chemokines are key regulators of leukocyte activation and recruitment to sites of inflammation. Of particular relevance in rheumatoid arthritis (RA), the chemokine receptors CCR1…Abstract Number: 1793 • 2013 ACR/ARHP Annual Meeting
Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 52-wk study (NCT01197521) compared Fosta vs placebo (PBO) + methotrexate (MTX) in patients (pts) with active…Abstract Number: 1794 • 2013 ACR/ARHP Annual Meeting
The Jak Inihibitor Tofacitinib Suppresses Synovial Jak-Stat Signalling In Rheumatoid Arthritis
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The specific JAK-STAT (signal transducer and activator of…Abstract Number: 1795 • 2013 ACR/ARHP Annual Meeting
An Active Metabolite Contributes To The Pharmacodynamics and Efficacy Of GLPG0634, a Selective JAK1 Inhibitor
Background/Purpose: GLPG0634 is an orally-available, selective inhibitor of Janus kinase 1 (JAK1). Through inhibition of signaling pathways for cytokines involved in rheumatoid arthritis (RA), non-selective…Abstract Number: 1796 • 2013 ACR/ARHP Annual Meeting
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 12-week blinded phase…Abstract Number: 1797 • 2013 ACR/ARHP Annual Meeting
A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis
Background/Purpose: To characterize the safety and efficacy of INCB039110, a novel and selective JAK1 inhibitor, in patients with active RA. Methods: This phase 2, multicenter…Abstract Number: 1798 • 2013 ACR/ARHP Annual Meeting
Ustekinumab For The Treatment Of Patients With Active Ankylosing Spondylitis: Results Of a 28-Week, Prospective, Open-Label, Proof-Of-Concept Study (TOPAS)
Background/Purpose: In contrast to other inflammatory rheumatic diseases, such as rheumatoid arthritis, the therapeutic options in ankylosing spondylitis (AS) with predominant axial manifestations are limited…Abstract Number: 1799 • 2013 ACR/ARHP Annual Meeting
Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Background/Purpose: Previous reports of RAPID-axSpA have demonstrated the efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in patients (pts) with axial spondyloarthritis…Abstract Number: 1800 • 2013 ACR/ARHP Annual Meeting
Persistent Fatty Lesions In The Vertebrae In Ankylosing Spondylitis Favor Subsequent New Syndesmophytes: Imaging Results Of a Phase III, Randomized, Placebo-Controlled Study
Background/Purpose: In ankylosing spondylitis (AS), it is hypothesized that stepwise pathologic changes in the spine begin with active inflammation, then fatty degeneration (Fat), leading to…Abstract Number: 1801 • 2013 ACR/ARHP Annual Meeting
Relationship Between MRI and Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Therapy
Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…Abstract Number: 1802 • 2013 ACR/ARHP Annual Meeting
A Major Clinical Response To Anti-Tumor Necrosis Factor Agents Is Associated With a Reduced Development Of Fatty Changes In The Spine Of Patients With Ankylosing Spondylitis
Background/Purpose: Fatty changes (FC) on T1-weighted magnetic resonance images (MRI) have been described in the spine of patients with ankylosing spondylitis (AS). Such lesions were…Abstract Number: 1803 • 2013 ACR/ARHP Annual Meeting
Is Site Of Back Pain Related To Location Of Inflammatory and Structural Lesions On MRI In Patients With Chronic Back Pain?
Background/Purpose: Pain has found to be related to inflammatory lesions in thoracic, lumbar and sacroiliac joints (SIJ) sites and to structural lesions in the SIJ…Abstract Number: 1804 • 2013 ACR/ARHP Annual Meeting
Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus
Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…Abstract Number: 1806 • 2013 ACR/ARHP Annual Meeting
Association Between Hydroxychloroquine Exposure and Incidence Of Diabetes Mellitus In Systemic Lupus Erythematosus
Background/Purpose: Diabetes mellitus is one of the SLICC/ACR Damage Index items and a recognized risk factor for cardiovascular disease and renal failure. In rheumatoid arthritis,…